• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度南部两批早产儿后部过强型视网膜病变患者:对一级、二级和三级预防的启示。

Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.

机构信息

Pediatric Retina & Ocular Oncology Division, Aravind Eye Hospital, Coimbatore, India.

Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago.

出版信息

J AAPOS. 2019 Oct;23(5):264.e1-264.e4. doi: 10.1016/j.jaapos.2019.05.014. Epub 2019 Sep 12.

DOI:10.1016/j.jaapos.2019.05.014
PMID:31521847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7219568/
Abstract

BACKGROUND

Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy.

METHODS

The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP.

RESULTS

A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]).

CONCLUSIONS

The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.

摘要

背景

由于氧监测不佳(一级预防),中低收入国家(LMICs)早产儿常发生侵袭性后部早产儿视网膜病变(APROP),其视觉预后较差。本研究旨在比较接受抗血管内皮生长因子(anti-VEGF)治疗与激光治疗的 APROP 眼的结局。

方法

回顾性分析了在印度南部同一机构接受 anti-VEGF(2010-2018 年)治疗的 APROP 眼队列和接受激光光凝治疗的眼队列(2002-2010 年)的病历,并进行比较。主要结局是在急性 ROP 消退过程中发生视网膜脱离的眼的比例。

结果

共纳入 398 只患 APROP 的 199 只早产儿的眼:168 只眼接受光凝治疗;230 只眼接受 anti-VEGF 治疗。与较近的队列相比,2002 年至 2010 年间,被诊断为 APROP 的婴儿体重更重(P<0.001)、年龄更大(P<0.001)、吸氧天数更少(P=0.02)。在激光治疗组中,168 只眼中有 17 只(10%)发生视网膜脱离(7 只,5 期;12 只,4 期),而 230 只 anti-VEGF 治疗组中只有 3 只(1%)发生视网膜脱离(均为 4 期,P=0.002)。

结论

与激光治疗组相比,anti-VEGF 治疗组的视网膜脱离发生率显著降低。在没有随机试验的情况下,这些数据表明,anti-VEGF 可能会导致更好的解剖学结局,尽管关于剂量、时机和风险仍存在疑问。

相似文献

1
Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.印度南部两批早产儿后部过强型视网膜病变患者:对一级、二级和三级预防的启示。
J AAPOS. 2019 Oct;23(5):264.e1-264.e4. doi: 10.1016/j.jaapos.2019.05.014. Epub 2019 Sep 12.
2
Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.早产儿视网膜病变激光治疗与玻璃体内抗血管内皮生长因子治疗后视网膜脱离。
Ophthalmology. 2021 Aug;128(8):1188-1196. doi: 10.1016/j.ophtha.2020.12.028. Epub 2020 Dec 31.
3
Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.玻璃体内注射雷珠单抗初始治疗后侵袭性早产儿视网膜病变的结局和预后因素
BMC Ophthalmol. 2018 Jun 26;18(1):150. doi: 10.1186/s12886-018-0815-1.
4
Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.玻璃体内注射阿柏西普与激光光凝治疗早产儿视网膜病变的疗效比较
J Pediatr Ophthalmol Strabismus. 2020 Jan 1;57(1):54-60. doi: 10.3928/01913913-20191104-01.
5
Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.激光光凝与玻璃体内注射贝伐单抗治疗 1 型早产儿视网膜病变后短期视网膜脱离风险。
J AAPOS. 2019 Oct;23(5):260.e1-260.e4. doi: 10.1016/j.jaapos.2019.05.013. Epub 2019 Sep 9.
6
Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.1 型 ROP 和 APROP 中抗血管内皮生长因子注射联合激光光凝治疗的效果。
Int Ophthalmol. 2022 Jan;42(1):95-101. doi: 10.1007/s10792-021-02004-8. Epub 2021 Aug 20.
7
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.用于治疗早产儿视网膜病变的抗血管内皮生长因子(VEGF)药物。
Cochrane Database Syst Rev. 2016;2:CD009734. doi: 10.1002/14651858.CD009734.pub2. Epub 2016 Feb 27.
8
Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.玻璃体切除术联合抗血管内皮生长因子治疗伴广泛新生血管增殖的4期早产儿视网膜病变
J Pediatr Ophthalmol Strabismus. 2020 Jan 1;57(1):61-66. doi: 10.3928/01913913-20191030-01.
9
Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.贝伐单抗与激光治疗侵袭性早产儿视网膜病变后的消退率:8年回顾性分析
Med Sci Monit. 2016 Apr 10;22:1192-209. doi: 10.12659/msm.897095.
10
A rare case of aggressive posterior retinopathy of prematurity presenting with exudative retinal detachment.一例罕见的伴有渗出性视网膜脱离的早产儿后部进展性视网膜病变。
J AAPOS. 2021 Feb;25(1):47-50. doi: 10.1016/j.jaapos.2020.08.007. Epub 2020 Nov 2.

引用本文的文献

1
Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity.玻璃体内注射贝伐单抗单药治疗与联合激光光凝和玻璃体内注射贝伐单抗治疗在同一时段治疗早产儿侵袭性视网膜病变的比较。
Int Ophthalmol. 2024 Jul 2;44(1):305. doi: 10.1007/s10792-024-03171-0.
2
Quantification of Early Neonatal Oxygen Exposure as a Risk Factor for Retinopathy of Prematurity Requiring Treatment.作为需要治疗的早产儿视网膜病变危险因素的早期新生儿氧暴露量化
Ophthalmol Sci. 2021 Oct 22;1(4):100070. doi: 10.1016/j.xops.2021.100070. eCollection 2021 Dec.
3

本文引用的文献

1
Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.玻璃体内注射雷珠单抗初始治疗后侵袭性早产儿视网膜病变的结局和预后因素
BMC Ophthalmol. 2018 Jun 26;18(1):150. doi: 10.1186/s12886-018-0815-1.
2
Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.抗血管内皮生长因子治疗早产儿视网膜病变 1 型:美国眼科学会报告。
Ophthalmology. 2017 May;124(5):619-633. doi: 10.1016/j.ophtha.2016.12.025. Epub 2017 Mar 22.
3
Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure.
Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
比较玻璃体腔内抗血管内皮生长因子药物与激光光凝治疗早产儿视网膜病变的不良事件:系统评价。
Int Ophthalmol. 2023 Mar;43(3):1027-1062. doi: 10.1007/s10792-022-02480-6. Epub 2022 Oct 10.
4
External Validation of a Retinopathy of Prematurity Screening Model Using Artificial Intelligence in 3 Low- and Middle-Income Populations.人工智能在 3 个中低收入人群中对早产儿视网膜病变筛查模型的外部验证。
JAMA Ophthalmol. 2022 Aug 1;140(8):791-798. doi: 10.1001/jamaophthalmol.2022.2135.
5
Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab.侵袭性早产儿视网膜病变:玻璃体内注射贝伐单抗后的长期预后
Front Pediatr. 2022 Feb 11;10:778585. doi: 10.3389/fped.2022.778585. eCollection 2022.
6
Aggressive Retinopathy of Prematurity in a Larger and Less Preterm Infant: A Review of Possible Risk Factors.较大且早产程度较轻的婴儿发生的侵袭性早产儿视网膜病变:可能的危险因素综述
Cureus. 2021 Nov 4;13(11):e19267. doi: 10.7759/cureus.19267. eCollection 2021 Nov.
7
Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.早产儿视网膜病变再激活后重复注射雷珠单抗的临床疗效。
Eye (Lond). 2022 Nov;36(11):2137-2143. doi: 10.1038/s41433-021-01814-5. Epub 2021 Oct 28.
8
Applications of Artificial Intelligence for Retinopathy of Prematurity Screening.人工智能在早产儿视网膜病变筛查中的应用。
Pediatrics. 2021 Mar;147(3). doi: 10.1542/peds.2020-016618.
9
Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.早产儿视网膜病变激光治疗与玻璃体内抗血管内皮生长因子治疗后视网膜脱离。
Ophthalmology. 2021 Aug;128(8):1188-1196. doi: 10.1016/j.ophtha.2020.12.028. Epub 2020 Dec 31.
10
Aggressive Posterior Retinopathy of Prematurity: Clinical and Quantitative Imaging Features in a Large North American Cohort.早产儿后部急性视网膜病变:一项大型北美队列的临床和定量成像特征。
Ophthalmology. 2020 Aug;127(8):1105-1112. doi: 10.1016/j.ophtha.2020.01.052. Epub 2020 Feb 7.
高氧暴露后早产儿视网膜病变低风险患儿荧光素血管造影的血管变化
Int J Retina Vitreous. 2017 Jan 16;3:2. doi: 10.1186/s40942-016-0055-6. eCollection 2017.
4
OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.I区1型早产儿视网膜病变激光治疗与激光联合贝伐单抗治疗后的疗效
Retina. 2017 Jan;37(1):88-96. doi: 10.1097/IAE.0000000000001125.
5
Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.玻璃体内注射贝伐单抗单药治疗后复发性早产儿视网膜病变的临床管理
Ophthalmology. 2016 Sep;123(9):1845-55. doi: 10.1016/j.ophtha.2016.04.028. Epub 2016 May 27.
6
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.玻璃体内注射贝伐单抗单药治疗1型阈值前期、阈值期及侵袭性早产儿视网膜病变——来自土耳其的27个月随访结果
Graefes Arch Clin Exp Ophthalmol. 2015 Oct;253(10):1677-83. doi: 10.1007/s00417-014-2867-0. Epub 2014 Dec 14.
7
Aggressive posterior retinopathy of prematurity in large preterm babies in South India.印度南部大型早产儿的侵袭性后部早产儿视网膜病变。
Arch Dis Child Fetal Neonatal Ed. 2012 Sep;97(5):F371-5. doi: 10.1136/fetalneonatal-2011-301121. Epub 2012 May 18.
8
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.玻璃体内注射贝伐单抗治疗 3 期及以上早产儿视网膜病变的疗效。
N Engl J Med. 2011 Feb 17;364(7):603-15. doi: 10.1056/NEJMoa1007374.
9
The International Classification of Retinopathy of Prematurity revisited.再探早产儿视网膜病变国际分类法。
Arch Ophthalmol. 2005 Jul;123(7):991-9. doi: 10.1001/archopht.123.7.991.
10
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.早产儿视网膜病变治疗的修订指征:早产儿视网膜病变早期治疗随机试验结果
Arch Ophthalmol. 2003 Dec;121(12):1684-94. doi: 10.1001/archopht.121.12.1684.